Kingsley Lawrence D

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-019140 · wk-form4_1714428780.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,233.79

F1 · balance_after: The reported transaction involved the crediting of 1,801 deferred stock units granted under the Polaris Inc. 2024 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 1,801 newly acquired deferred stock units, and 438.73 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001628280-24-014180 · wk-form4_1712007844.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,025

F1 · shares: These shares were issued in connection with the Reporting Person's election to receive his or her quarterly retainer for director services in the form of vested shares rather than cash.

SEC source: 0001628280-24-000224 · wk-form4_1704318312.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,346

F1 · shares: These shares were issued in connection with the Reporting Person's election to receive his or her quarterly retainer for director services in the form of vested shares rather than cash.

SEC source: 0001628280-23-033474 · wk-form4_1696277037.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,511

F1 · shares: These shares were issued in connection with the Reporting Person's election to receive his or her quarterly retainer for director services in the form of vested shares rather than cash.

SEC source: 0001628280-23-021320 · wk-form4_1686172217.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,941

F1 · shares: Represents restricted stock units that will vest in four equal quarterly installments on September 15, 2023, December 15, 2023, March 15, 2024, and June 15, 2024, subject to the non-employee director's continued service on the Board through each such vesting date.

SEC source: 0000874716-23-000080 · wf-form4_168453017782121.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 339

Underlying: Common Stock · 82 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-23-000080 · wf-form4_168453017782121.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257

Underlying: Common Stock · 257 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-23-000080 · wf-form4_168453017782121.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 851

Underlying: Common Stock · 206 shares

Expires 2033-05-16

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-23-000080 · wf-form4_168453017782121.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 645

Underlying: Common Stock · 645 shares

Expires 2033-05-16

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-23-000055 · wf-form4_168418631096535.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 120 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-23-000055 · wf-form4_168418631096535.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120

Underlying: Common Stock · 344 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-23-000055 · wf-form4_168418631096535.xml · nonDerivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,544

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-23-000055 · wf-form4_168418631096535.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-23-014654 · wf-form4_168297573313840.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,994.06

F1 · balance_after: The reported transaction involved the crediting of 1,380 deferred stock units granted under the Polaris Industries Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 1,380 newly acquired deferred stock units, and 113.14 common stock equivalents and 256.81 deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001628280-22-017427 · wf-form4_165549674119704.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,091

F1 · shares: Represents restricted stock units that will vest in four equal quarterly installments on September 15, 2022, December 15, 2022, March 15, 2023, and June 15, 2023, subject to the non-employee director's continued service on the Board through each such vesting date.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 8

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464

Underlying: Common Stock · 78 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 7

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 542

Underlying: Common Stock · 224 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 6

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 766

Underlying: Common Stock · 120 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F3 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F5 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 5

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 646

Underlying: Common Stock · 344 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F5 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,274

Underlying: Common Stock · 329 shares

Expires 2032-05-11

F3 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F5 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010574 · doc1.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945

Underlying: Common Stock · 945 shares

Expires 2032-05-10

F5 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010574 · doc1.xml · nonDerivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-010574 · doc1.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,002

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-22-011797 · wf-form4_165152724458322.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,244.11

F1 · balance_after: The reported transaction involved the crediting of 1,486 deferred stock units granted under the Polaris Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors (DC Plan). The total reported in column 5 includes the 1,486 newly acquired deferred stock units, and 99.56 common stock equivalents and 194.11 deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0000950103-21-020485 · dp164362_4-kingsley.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,817

F1 · shares: Represents restricted stock units ("RSUs") that will vest in two installments with 3,569 RSUs vesting on March 15, 2022 and 2,248 RSUs vesting on June 15, 2022, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0000950103-21-016334 · dp160251_4-kingsley.xml · nonDerivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 350,000

F2 · kind: Reflects shares of Common Stock purchased by the Diane Kingsley Revocable Trust. Members of the Reporting Person's immediate family are beneficial holders of the Diane Kingsley Revocable Trust, and the Reporting Person may be deemed to exercise voting and investment power over such shares of Common Stock. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0000950103-21-016334 · dp160251_4-kingsley.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 150,000

F1 · kind: Reflects shares of Class A Common Stock of the Issuer ("Common Stock") purchased by the Lawrence D. Kingsley 2015 Family Irrevocable Trust. Members of the Reporting Person's immediate family are beneficial holders of the Lawrence D. Kingsley 2015 Family Irrevocable Trust, and the Reporting Person may be deemed to exercise voting and investment power over such shares of Common Stock. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 975

Underlying: Common Stock · 252 shares

Expires 2031-05-11

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302

Underlying: Common Stock · 78 shares

Expires not disclosed

F1 · derivative.exercise_price: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F4 · price: Not applicable.

F1 · derivative.exercise_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F4 · price: Not applicable.

F1 · derivative.exercise_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001209191-21-029574 · doc4.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,464.44

F1 · balance_after: The reported transaction involved the crediting of 1,018 deferred stock units granted under the Polaris Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors (DC Plan). The total reported in column 5 includes the 1,018 newly acquired deferred stock units, and 293.55 common stock equivalents and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001246360-21-000343 · form.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,295.868

F1 · shares: Shares delivered as compensation for service as a director under the 2020 Long-Term Incentives Plan.

SEC source: 0001246360-20-001557 · form.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,136.868

F1 · shares: Shares delivered as compensation for service as a director under the 2020 Long-Term Incentives Plan.

SEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 487

Underlying: Common Stock · 487 shares

Expires 2030-05-05

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Chairman of the Board.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,279

Underlying: Common Stock · 1,279 shares

Expires 2030-05-05

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,740

Underlying: Common Stock · 141 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Chairman of the Board.

F4 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-20-009377 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,599

Underlying: Common Stock · 370 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F4 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001209191-20-026803 · doc4.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,152.9

F1 · balance_after: The reported transaction involved the crediting of 1,833 deferred stock units granted under the Polaris Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors (DC Plan). The total reported in column 5 includes the 1,833 newly acquired deferred stock units, and 175.44 common stock equivalents and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001246360-20-000406 · form.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,646.868

F1 · shares: Shares delivered as compensation for service as a director under the 2003 Directors Stock Plan.

SEC source: 0001567619-19-022599 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277

Underlying: Common Stock · 277 shares

Expires 2029-11-30

F3 · derivative.exercise_price: November 29, 2019 closing price of Issuer common stock on the NASDAQ Global Select Market.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 6, 2020.

SEC source: 0001567619-19-022599 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,229

Underlying: Common Stock · 82 shares

Expires not disclosed

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person upon being named non-executive Chairman of the Board effective November 1, 2019 until the 2020 annual meeting of stockholders.

F2 · derivative.exercise_price: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F5 · price: Not applicable.

F2 · derivative.exercise_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001246360-19-002150 · form.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,448.868

F1 · shares: Shares delivered as compensation for service as a director under the 2003 Directors Stock Plan.

SEC source: 0001209191-19-052395 · doc4.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,144.46

F1 · balance_after: The reported transaction involved the crediting of 271.49 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 271.49 newly acquired CSEs, and 65.29 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001567619-19-016072 · doc1.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,778

SEC source: 0001209191-19-040771 · doc4.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,807.68

F1 · balance_after: The reported transaction involved the crediting of 270.29 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 270.29 newly acquired CSEs, and 63.76 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.

SEC source: 0001567619-19-010454 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010454 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,147

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001209191-19-026457 · doc4.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,473.62

F1 · balance_after: The reported transaction involved the crediting of 1,372 deferred stock units granted under the Polaris Industries Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors.